We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis
Comparing long-acting and short-acting GLP-1 drugs for weight loss and metabolism in type 2 diabetes
AI simplified
Abstract
Twelve randomized controlled trials involving 2751 patients were analyzed to compare the effects of long-acting and short-acting GLP-1 receptor agonists.
- Long-acting GLP-1 receptor agonists led to a greater reduction in body weight compared to short-acting ones.
- A significant improvement in glycosylated hemoglobin (HbA1c) levels was observed with long-acting GLP-1 receptor agonists.
- Fasting plasma glucose levels decreased more with long-acting GLP-1 receptor agonists than with short-acting counterparts.
- Long-acting GLP-1 receptor agonists were associated with a greater reduction in total cholesterol and low-density lipoprotein (LDL) levels.
- No significant treatment differences were found for triglycerides and high-density lipoprotein (HDL) levels.
AI simplified
Key numbers
-0.65
Weight Loss Reduction
Mean difference in body weight from baseline.
-0.43
HbA1c Reduction
Mean difference in HbA1c levels.
-0.77
Fasting Plasma Glucose Reduction
Mean difference in fasting plasma glucose levels.